Colombia Glucoamylase Market Size & Outlook, 2026-2034
Colombia Glucoamylase Market Insights
- Based on Reed Intelligence findings, the Colombia Glucoamylase Market reached USD 4.73 Million in 2025 and is estimated to attain USD 8.57 Million by 2034.
- From 2026 to 2034, the Colombia market is expected to grow at a steady CAGR of 6.79%.
- Within the Type category, Microbial Glucoamylase dominated in 2025 in terms of market size contribution.
- Over the forecast period, Plant-Based Glucoamylase is forecasted to deliver the fastest growth, positioning it as the most lucrative Type segment.
![Colombia Glucoamylase Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/colombia-glucoamylase-market-colombia-type-111733.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Colombia accounted for 0.45% of the global Glucoamylase Market size.
- By 2034, United States is expected to lead the global Glucoamylase Market in terms of market size.
- Within LATAM, Brazil is projected to dominate the regional Glucoamylase Market size by 2034.
- Mexico is identified as the fastest-growing market in LATAM, anticipated to reach USD 31.55 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 4.73 Million |
| Market Size In 2034 | USD 8.57 Million |
| Largest segment | Microbial Glucoamylase |
| Units | Revenue in USD Million |
| CAGR | 6.79% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Application |
|
| End-Use Industry |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Colombia Glucoamylase Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microbial Glucoamylase | XX.x | XX.x | XX.x | 2.26 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Plant-Based Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Genetically Engineered Glucoamylase | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Colombia Glucoamylase Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Processing | XX.x | XX.x | XX.x | 1.93 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bioethanol Production | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Animal Feed | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Colombia Glucoamylase Market End-Use Industry 2026-2034 (USD Million)
| End-Use Industry | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food & Beverage Industry | XX.x | XX.x | XX.x | 1.9 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Energy & Biofuel Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceutical & Biotechnology Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Agriculture Industry | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
